Showing 15 posts of 285 posts found.

AZ-BMS launch Onglyza in Europe

October 19, 2009
Sales and Marketing AZ, BMS, DPP-4, Onglyza, diabetes

 Bristol-Myers Squibb and AstraZeneca’s long-awaited type II diabetes drug Onglyza has been launched in the UK, its first European market.Designed …

Manufacturing facility news in brief

September 14, 2009
Manufacturing and Production BMS

Pharmafocus' round-up of manufacturing facility news includes plant disposals by BMS and Sanofi-Aventis, a new build for device company Haselmeier …

BMS profits surge ahead

July 30, 2009
Sales and Marketing BMS

Bristol Myers-Squibb's earnings growth massively outstripped its income in the second quarter of the year. The company saw its net …

BMS buys Medarex for $2.1 billion

July 24, 2009
Research and Development, Sales and Marketing BMS, MA, Medarex

Bristol-Myers Squibb is to spend $2.1 billion in buying Medarex, the human antibody drug discovery specialists. Princeton-based Medarex is best …

BMS launches cancer website

July 15, 2009
Medical Communications, Sales and Marketing BMS, Cancer, digi

Bristol-Myers Squibb has launched a new website for sufferers of chronic myeloid leukaemia (CML), a cancer of the blood. …

Onglyza and Cimzia recommended by CHMP

July 2, 2009
Research and Development, Sales and Marketing AZ, BMS, EMEA, Europe, Ongylza

Bristol-Myers Squibb andAstraZeneca's type II diabetes treatment Onglyza is among the brands to have received positive opinions from the Committee …

BMS turns in solid first quarter results

May 1, 2009
Sales and Marketing BMS

Bristol-Myers Squibb turned in respectable figures for the first quarter of 2008, with net income up 5% to $921 million. …

Plavix sales help BMS into profit

January 29, 2009
Sales and Marketing BMS, Plavix

Strong fourth quarter sales of its blockbuster blood thinner Plavix have helped Bristol-Myers Squibb back into the black. Net earnings …

BMS denies further 10% staff cut

January 2, 2009
Sales and Marketing BMS, restructure

Bristol Myers Squibb has denied claims it is making a further 10% reduction to its work force, and said any …

BMS to cut extra 10% from workforce

December 17, 2008
Sales and Marketing BMS

Bristol-Myers Squibb is to cut its global workforce by an extra 10% before 2010, in order to reduce costs and …

BMS breast cancer drug rejected

November 27, 2008
Sales and Marketing BMS, Cancer, breast cancer

Bristol-Myers Squibb's breast cancer drug Ixempra has suffered a setback in the EU over safety concerns.The Committee for Medicinal Products …

Roche maintains sales growth for Q3

November 2, 2007
Sales and Marketing BMS

Third quarter figures show Roche's top-selling products have all posted double-digit advances on the same period in 2006. Growth for …

BMS expands Indian biotech collaboration

March 21, 2007
Research and Development BMS, India

Bristol-Myers Squibb will establish a new integrated drug development facility in Bangalore as part of an expansion of its R&D …

New UK headquarters for Bristol-Myers Squibb

December 5, 2005
Sales and Marketing BMS, UK

Bristol-Myers Squibb UK has moved into a new state-of-the-art head office in Uxbridge.The £5.5 million building houses over 200 employees, …

Latest content